Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. - Wikidata - wikimedia - TriplyDB

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

http://www.wikidata.org/entity/Q34255603

about

The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis.

P2860

Q34451346-55F21AAF-E222-4573-A6E5-431F7A0962A8 Q37599605-B26E5715-BD8C-4B21-A7D1-CC77E944BDD6 Q47365108-6E55A230-D604-4C9C-986D-487ABB621980

P2860

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

http://www.wikidata.org/entity/Q34255603

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@ast

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@en

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@nl

type

label

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@ast

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@en

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@nl

prefLabel

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@ast

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@en

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@nl

P1433

Q34255603-05F7C275-2D37-46EA-98F1-1030F9685D6C

P1476

Q34255603-D84E9B0E-0EE1-45BA-B51C-65BF394DB5B8

P2093

Q34255603-0518F2F9-7AB1-499D-B0E5-1852C487FE11

Q34255603-08E102C0-B065-475A-8DE3-9226280B4DBE

Q34255603-1F115CA0-2FAA-4892-AD7F-1FEF4A596C74

Q34255603-22C35E3B-E79D-4B7F-8A16-D86E151ADE65

Q34255603-22CAC18C-7FEA-49EE-A904-2B2521FBD286

Q34255603-30777407-4E75-4BCB-9558-E1525BC4E741

Q34255603-368F130F-DE8D-4C86-95C7-AB3C7B527311

Q34255603-3E6E01CF-05A2-45C2-AD61-C6FE45FB9F2E

Q34255603-424FF21F-4795-4EB8-8154-CDA33F16547D

Q34255603-52EAFD57-5993-4A02-B60A-F2EDD41307B3

P2860

Q34255603-10729E04-C1F3-40C1-BA39-CBCFE29CEC09

Q34255603-17122E6D-9FFB-4FB5-A627-DF3C473D3179

Q34255603-19AB9A40-7817-4C08-AB0F-40D92236018A

Q34255603-1B8795E6-8BC6-45E8-9250-E24995F4F262

Q34255603-3207C88C-2B84-4921-9C52-97A2A0CEE06A

Q34255603-3CAA4733-D8B6-4F30-B559-3096B4CBF9D3

Q34255603-43152D5E-B2F0-43B1-A02A-15D0A2AA7086

Q34255603-4A9D3489-07C2-40FD-9BD9-D71C6C7000FA

Q34255603-53A0E211-1780-4AC0-825D-4A8435772A42

Q34255603-54F9E51B-8302-47F6-AB8B-5769EB651094

P304

Q34255603-3E1279C0-F088-4264-A2E8-6EABE85212B5

P31

Q34255603-1EAA4916-E08A-4561-815E-5D4C709F6CC1

P356

Q34255603-9EC23515-78FD-408C-A6C8-E5DF08E5B49A

P433

Q34255603-803810F5-037A-4FE9-B8A8-9EB11291D1C5

P478

Q34255603-188EBC74-016E-46FA-AC2D-D54B4AA4DD27

P577

Q34255603-0B56FEB3-0335-4866-9802-D88587DD68BF

P5875

Q34255603-42515931-1F19-4FD5-A5E0-F364B7C91143

P698

Q34255603-ADB624D3-A898-42F4-9518-CAE5C5D86E34

P921

Q34255603-395F72B0-43FB-4D76-805B-69AEAF29DFE0

P932

Q34255603-63B2707B-A436-4373-BBBF-092A544EEFA5

P356

JKMS.2010.25.11.1601

P1433

Journal of Korean Medical Science

P1476

Clinical benefit of low molecu ...... ycoprotein IIb/IIIa inhibitor.

@en

P2093

Chong Jim Kim

http://www.w3.org/2001/XMLSchema#string

Donghoon Choi

http://www.w3.org/2001/XMLSchema#string

Hyoung Doo Kim

http://www.w3.org/2001/XMLSchema#string

In Ho Chae

http://www.w3.org/2001/XMLSchema#string

In Whan Seong

http://www.w3.org/2001/XMLSchema#string

Jang Ho Bae

http://www.w3.org/2001/XMLSchema#string

Jay Young Rhew

http://www.w3.org/2001/XMLSchema#string

Jei Keon Chae

http://www.w3.org/2001/XMLSchema#string

Jeong Gwan Cho

http://www.w3.org/2001/XMLSchema#string

Ju Yeal Baek

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

The impact of initial treatment delay using primary angioplasty on mortality among patients with acute myocardial infarction: from the Korea acute myocardial infarction registry

Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.

Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry).

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

P304

1601-1608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2010.25.11.1601

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47718684

http://www.w3.org/2001/XMLSchema#string

P698

21060749

http://www.w3.org/2001/XMLSchema#string

P921

P932

2966997

http://www.w3.org/2001/XMLSchema#string